COGT
Cogent Biosciences, Inc. NASDAQ Listed Mar 29, 2018$34.80
Mkt Cap $5.6B
52w Low $4.55
77.2% of range
52w High $43.73
50d MA $36.42
200d MA $27.87
P/E (TTM)
-14.4x
EV/EBITDA
-7.1x
P/B
3.9x
Debt/Equity
0.4x
ROE
-51.7%
P/FCF
-9.0x
RSI (14)
—
ATR (14)
—
Beta
0.47
50d MA
$36.42
200d MA
$27.87
Avg Volume
2.0M
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
200 Cambridge Park Drive · Waltham, MA 02140 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | BMO | -0.51 | -0.55 | -7.8% | 37.62 | +1.0% | +1.9% | +0.0% | -0.0% | -2.6% | -0.7% | — |
| Nov 7, 2025 | BMO | -0.54 | -0.50 | +7.4% | 14.82 | +121.1% | +119.0% | +0.0% | +3.0% | +5.5% | -4.1% | — |
| Aug 5, 2025 | BMO | -0.55 | -0.53 | +3.6% | 11.36 | -2.7% | -3.4% | +0.0% | -1.0% | +0.9% | -0.3% | — |
| May 6, 2025 | BMO | -0.56 | -0.52 | +7.1% | 4.70 | -1.1% | +0.4% | +0.0% | +5.5% | -3.4% | +6.7% | — |
| Feb 25, 2025 | BMO | -0.59 | -0.09 | +84.7% | 6.99 | +3.3% | -4.0% | +0.0% | +4.2% | +7.7% | -7.0% | — |
| Nov 12, 2024 | BMO | -0.55 | -0.64 | -16.4% | 10.38 | +0.0% | +0.2% | +0.0% | -7.2% | -7.8% | +1.0% | — |
| Aug 6, 2024 | BMO | -0.55 | -0.59 | -7.3% | 9.26 | -0.6% | -6.8% | +0.0% | +3.0% | -3.5% | -0.9% | — |
| May 7, 2024 | BMO | -0.50 | -0.62 | -24.0% | 7.76 | -0.1% | -2.1% | +0.0% | +4.2% | -4.5% | -2.8% | — |
| Feb 26, 2024 | BMO | -0.54 | -0.63 | -16.7% | 7.50 | +4.7% | -0.1% | +0.0% | -2.0% | -4.6% | +3.3% | — |
| Nov 2, 2023 | BMO | -0.50 | -0.64 | -28.0% | 8.56 | +1.6% | -0.6% | +0.0% | -1.9% | +1.8% | -13.5% | — |
| Aug 8, 2023 | BMO | -0.53 | -0.59 | -11.3% | 11.87 | -0.1% | -0.3% | +0.0% | +1.6% | -0.2% | +1.0% | — |
| May 9, 2023 | BMO | -0.58 | -0.54 | +6.9% | 12.13 | +1.2% | -3.9% | +0.0% | -2.4% | +1.3% | +3.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $35.68 | $35.68 | +0.0% | -0.7% | -3.0% | +0.7% | -3.6% | +6.1% |
| Feb 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $37.62 | $38.00 | +1.0% | +1.9% | -0.0% | -2.6% | -0.7% | +5.7% |
| Jan 21 | Wedbush | Maintains | Outperform → Outperform | — | $39.90 | $39.96 | +0.2% | +0.0% | -0.9% | -7.2% | +3.2% | +1.7% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.26 | $34.46 | +0.6% | +1.5% | +4.3% | -1.9% | -0.6% | -1.7% |
| Dec 19 | JP Morgan | Maintains | Overweight → Overweight | — | $37.90 | $38.58 | +1.8% | +4.4% | -0.5% | +2.1% | -1.1% | -2.1% |
| Dec 8 | Needham | Maintains | Hold → Hold | — | $38.77 | $43.07 | +11.1% | +3.9% | -4.4% | +1.7% | +2.2% | +5.2% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.26 | $35.83 | +1.6% | -4.1% | -0.9% | +0.6% | -1.0% | +4.6% |
| Nov 11 | Baird | Maintains | Neutral → Neutral | — | $32.46 | $31.11 | -4.2% | +3.0% | +5.5% | -4.1% | -0.9% | +0.6% |
| Nov 10 | Leerink Partners | Maintains | Outperform → Outperform | — | $14.82 | $32.76 | +121.1% | +119.0% | +3.0% | +5.5% | -4.1% | -0.9% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.50 | $15.24 | -1.7% | -8.8% | +2.1% | +2.1% | +0.7% | +119.0% |
| Oct 21 | JP Morgan | Maintains | Overweight → Overweight | — | $16.22 | $16.60 | +2.3% | -2.2% | -6.4% | -0.1% | +2.0% | +7.1% |
| Aug 25 | Guggenheim | Maintains | Buy → Buy | — | $12.12 | $12.47 | +2.9% | -2.7% | +3.7% | +1.1% | -2.3% | +0.0% |
| Aug 7 | JP Morgan | Maintains | Overweight → Overweight | — | $10.97 | $10.87 | -0.9% | -1.0% | +0.9% | -0.3% | +5.7% | +3.7% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.36 | $11.05 | -2.7% | -3.4% | -1.0% | +0.9% | -0.3% | +5.7% |
| Jul 18 | Citigroup | Maintains | Buy → Buy | — | $12.20 | $12.47 | +2.2% | +2.4% | -1.5% | +1.2% | -0.6% | -1.5% |
| Jul 10 | JP Morgan | Maintains | Overweight → Overweight | — | $10.40 | $10.49 | +0.9% | +4.3% | +1.2% | +1.0% | +3.7% | +3.1% |
| Jul 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.35 | $9.65 | +3.2% | +4.6% | +6.3% | +4.3% | +1.2% | +1.0% |
| Jul 8 | Guggenheim | Maintains | Buy → Buy | — | $9.35 | $9.65 | +3.2% | +4.6% | +6.3% | +4.3% | +1.2% | +1.0% |
| Jul 8 | Baird | Maintains | Neutral → Neutral | — | $9.35 | $9.65 | +3.2% | +4.6% | +6.3% | +4.3% | +1.2% | +1.0% |
| Jul 7 | Jefferies | Maintains | Buy → Buy | — | $7.58 | $8.97 | +18.3% | +23.4% | +4.6% | +6.3% | +4.3% | +1.2% |
| Jul 7 | Leerink Partners | Maintains | Outperform → Outperform | — | $7.58 | $8.97 | +18.3% | +23.4% | +4.6% | +6.3% | +4.3% | +1.2% |
| Jun 17 | Needham | Maintains | Hold → Hold | — | $7.49 | $7.35 | -1.9% | +1.7% | -5.0% | -0.1% | +0.4% | -0.3% |
| May 29 | JP Morgan | Maintains | Overweight → Overweight | — | $4.88 | $5.09 | +4.3% | +12.9% | -1.3% | +3.1% | +3.2% | -2.6% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.98 | $4.96 | -0.4% | +6.6% | -6.2% | -0.6% | -2.6% | +1.2% |
| May 7 | Baird | Maintains | Neutral → Neutral | — | $4.70 | $4.65 | -1.1% | +0.4% | +5.5% | -3.4% | +6.7% | -2.7% |
| Feb 27 | Baird | Maintains | Neutral → Neutral | — | $6.71 | $6.74 | +0.4% | +4.2% | +7.7% | -7.0% | +2.4% | +7.0% |
| Feb 26 | Needham | Maintains | Hold → Hold | — | $6.99 | $7.22 | +3.3% | -4.0% | +4.2% | +7.7% | -7.0% | +2.4% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.57 | $7.61 | +0.5% | -2.6% | +10.2% | +0.1% | -1.2% | +2.1% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.50 | $8.77 | -7.7% | -2.4% | -10.0% | -2.3% | +1.3% | -0.8% |
| Dec 11 | Needham | Downgrade | Buy → Hold | — | $9.50 | $8.77 | -7.7% | -2.4% | -10.0% | -2.3% | +1.3% | -0.8% |
| Dec 10 | Needham | Maintains | Buy → Buy | — | $9.67 | $9.66 | -0.1% | -1.8% | -2.4% | -10.0% | -2.3% | +1.3% |
| Dec 9 | Needham | Maintains | Buy → Buy | — | $8.89 | $8.16 | -8.2% | +8.8% | -1.8% | -2.4% | -10.0% | -2.3% |
| Nov 14 | JP Morgan | Maintains | Overweight → Overweight | — | $10.40 | $10.44 | +0.4% | -7.2% | -7.8% | +1.0% | +0.8% | +0.2% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $10.38 | $10.38 | +0.0% | +0.2% | -7.2% | -7.8% | +1.0% | +0.8% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.72 | $11.56 | -1.4% | +1.3% | -15.8% | +4.9% | -4.1% | +1.6% |
| Oct 24 | Needham | Maintains | Buy → Buy | — | $12.30 | $12.32 | +0.2% | -2.4% | -0.3% | -0.7% | +0.9% | +0.1% |
| Sep 24 | Citigroup | Maintains | Buy → Buy | — | $10.65 | $10.95 | +2.8% | +2.7% | -0.5% | +0.2% | +0.0% | -0.9% |
| Sep 5 | Baird | Maintains | Neutral → Neutral | — | $11.48 | $11.60 | +1.0% | -2.1% | -6.9% | +4.6% | -2.5% | +0.3% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.74 | $10.79 | +0.5% | +2.0% | +4.8% | -2.1% | -6.9% | +4.6% |
| Aug 7 | JP Morgan | Maintains | Overweight → Overweight | — | $9.26 | $9.20 | -0.6% | -6.8% | +3.0% | -3.5% | -0.9% | +3.2% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $9.26 | $9.20 | -0.6% | -6.8% | +3.0% | -3.5% | -0.9% | +3.2% |
| Jun 27 | Needham | Maintains | Buy → Buy | — | $8.10 | $8.14 | +0.5% | +4.2% | -0.1% | +6.0% | -7.8% | +1.5% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.43 | $8.40 | -0.4% | +4.4% | -3.4% | -1.6% | +5.1% | +1.1% |
| Jun 17 | Needham | Maintains | Buy → Buy | — | $8.43 | $8.40 | -0.4% | +4.4% | -3.4% | -1.6% | +5.1% | +1.1% |
| May 24 | Wedbush | Maintains | Neutral → Neutral | — | $7.49 | $7.52 | +0.4% | +9.7% | +2.3% | -8.3% | -5.4% | +9.9% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.56 | $7.68 | +1.6% | -2.8% | +0.0% | +5.0% | -3.2% | -0.4% |
| May 8 | Needham | Maintains | Buy → Buy | — | $7.76 | $7.75 | -0.1% | -2.1% | +4.2% | -4.5% | -2.8% | +0.0% |
| Feb 27 | JP Morgan | Maintains | Overweight → Overweight | — | $7.50 | $7.85 | +4.7% | -0.1% | -2.0% | -4.6% | +3.3% | -2.5% |
| Feb 26 | Baird | Downgrade | Outperform → Neutral | — | $7.44 | $7.25 | -2.6% | +0.8% | -0.1% | -2.0% | -4.6% | +3.3% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $7.44 | $7.25 | -2.6% | +0.8% | -0.1% | -2.0% | -4.6% | +3.3% |
No insider trades available.
8-K · 2.02
!! High
Cogent Biosciences, Inc. -- 8-K 2.02: Earnings Results
Cogent Biosciences released Q1 2026 earnings results, providing investors with updated financial performance and operational metrics for the quarter ending March 31, 2026.
May 5
8-K
Cogent Biosciences, Inc. -- 8-K Filing
Cogent Biosciences reported 2025 financial results and provided a business update on precision therapy development for genetically defined diseases, with no material transactions or deal announcements disclosed.
Feb 17
Data updated apr 25, 2026 2:31am
· Source: massive.com